Scandion Oncology As Stock Shares Owned By Insiders
| SCOL Stock | SEK 0.09 0.01 12.90% |
Scandion Oncology AS fundamentals help investors to digest information that contributes to Scandion Oncology's financial success or failures. It also enables traders to predict the movement of Scandion Stock. The fundamental analysis module provides a way to measure Scandion Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scandion Oncology stock.
Scandion |
Scandion Oncology AS Company Shares Owned By Insiders Analysis
Scandion Oncology's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Scandion Oncology Shares Owned By Insiders | 1.82 % |
Most of Scandion Oncology's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scandion Oncology AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.816% of Scandion Oncology AS are shares owned by insiders. This is 88.04% lower than that of the Healthcare sector and 87.19% lower than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is 82.0% higher than that of the company.
Scandion Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scandion Oncology's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scandion Oncology could also be used in its relative valuation, which is a method of valuing Scandion Oncology by comparing valuation metrics of similar companies.Scandion Oncology is currently under evaluation in shares owned by insiders category among its peers.
Scandion Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | 473.28 % | |||
| Current Valuation | (6.85 M) | |||
| Shares Outstanding | 40.71 M | |||
| Shares Owned By Insiders | 1.82 % | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 969.63 X | |||
| Gross Profit | (32.32 M) | |||
| EBITDA | (55.84 M) | |||
| Net Income | (51.7 M) | |||
| Cash And Equivalents | 131.54 M | |||
| Cash Per Share | 4.09 X | |||
| Current Ratio | 13.92 X | |||
| Book Value Per Share | 2.10 X | |||
| Cash Flow From Operations | (49.8 M) | |||
| Earnings Per Share | (1.74) X | |||
| Target Price | 3.87 | |||
| Number Of Employees | 14 | |||
| Beta | 0.48 | |||
| Market Capitalization | 111.79 M | |||
| Total Asset | 116.22 M | |||
| Net Asset | 116.22 M |
About Scandion Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scandion Oncology AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandion Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandion Oncology AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.